Pirfenidone is under clinical development by Avalyn Pharma and currently in Phase II for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease). According to GlobalData, Phase II drugs for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pirfenidone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pirfenidone overview

Pirfenidone (GP-101) is under development for the treatment of interstitial lung fibrosis , idiopathic pulmonary fibrosis (IPF) and chronic lung allograft dysfunction. It is an aerosol formulation administered through inhalation route for direct delivery to the lungs. The drug candidate is a small synthetic non-peptide molecule with both anti-inflammatory and anti-fibrotic activities.

Avalyn Pharma overview

Avalyn Pharma is a biopharma company which focuses on advanced therapies for the treatment of Idiopathic Pulmonary Fibrosis. Avalyn Pharma is headquartered in Seattle, Washington, the US.

For a complete picture of Pirfenidone’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.